AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2015
Sep 22, 2015
31523_dirs_2015-09-22_b38a09d5-0c07-47e3-a567-01fffcf93ef5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS INC (FOLD)
CIK: 0001178879
Period of Report: 2015-09-21
Reporting Person: Baird William D III (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-09-21 | Common stock | M | 15236 | $16.7783 | Acquired | 71811 | Direct |
| 2015-09-21 | Common stock | S | 15236 | $16.7783 | Disposed | 56575 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2015-09-21 | Stock Options (right to buy) | $3.53 | M | 5081 | Disposed | 2023-01-28 | Common stock (5081) | Direct |
| 2015-09-21 | Stock Options (right to buy) | $2.52 | M | 2655 | Disposed | 2023-06-18 | Common stock (2655) | Direct |
| 2015-09-21 | Stock Options (right to buy) | $2.45 | M | 7500 | Disposed | 2024-01-03 | Common stock (7500) | Direct |
Footnotes
F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2014.
F2: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.72 to $17.72. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F3: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.72 to $17.72. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.